-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Brilaroxazine in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brilaroxazine in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brilaroxazine in Parkinson's Disease Drug Details: RP-5063 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niraparib in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Niraparib in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Niraparib in Gastric Cancer Drug Details: Niraparib (MK-4827, Zejula) is an...
-
Product Insights
Psychosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psychosis - Drugs In Development, 2023’, provides an overview of the Psychosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psychosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Attention Deficit Hyperactivity Disorder (ADHD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Attention Deficit Hyperactivity Disorder (ADHD) - Drugs In Development, 2023’, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Bipolar Disorder (Manic Depression) – Drugs In Development, 2023
Global Markets Direct’s, ‘Bipolar Disorder (Manic Depression) - Drugs In Development, 2023’, provides an overview of the Bipolar Disorder (Manic Depression) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Pulmonary Arterial Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Arterial Hypertension - Drugs In Development, 2023’, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Major Depressive Disorder – Drugs In Development, 2023
Global Markets Direct’s, ‘Major Depressive Disorder - Drugs In Development, 2023’, provides an overview of the Major Depressive Disorder pipeline landscape. The report provides comprehensive information on the therapeutics under development for Major Depressive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Schizophrenia – Drugs In Development, 2023
Global Markets Direct’s, ‘Schizophrenia - Drugs In Development, 2023’, provides an overview of the Schizophrenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Pulmonary Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Hypertension - Drugs In Development, 2023’, provides an overview of the Pulmonary Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NZV-930 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NZV-930 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NZV-930 in Colorectal Cancer Drug Details: NZV-930 is under development for...